BristolMyersSquibb posts
FeedPosted Jan 5th 2009 3:30PM by Steven Halpern (RSS feed)
Filed under: Pfizer (PFE), Newsletters, Johnson and Johnson (JNJ), Bristol-Myers Squibb (BMY), Stocks to Buy, Best Stocks for 2009
Health care has long been considered a recession-resistant business. Given the current economic challenges, it's little surprise that in our survey of favorite stocks for the coming year, a number of leading advisors turned to this classic defensive sector.
In this year's Top Stock Picks from 75 advisors report, we found an intriguing group of medical-related stocks, from speculation in emerging biotech to well-established pharmaceutical firms, and from medical products makers to medical services firms focused on increasing health care efficiency and early disease detection.
Mike Cintolo, editor of The Cabot Market Letter, thinks Myriad Genetics (NASDAQ: MYGN) could be a "big winner in 2009," The company is a lead in the new field of cancer predisposition testing. For Mike's full report, read Top Stock Picks '09: Myriad Genetics.
Chuck Carlson, editor of The DRIP Investor, sees both quality and potential in Bristol-Myers Squibb (NYSE: BMY). For Chuck's full report, read Top Stock Picks '09: Bristol-Myers Squibb.
Continue reading Drug and health care stocks: The right prescription for 2009
Posted Dec 12th 2008 4:00PM by Jon Ogg (RSS feed)
Filed under: Ford Motor (F), General Motors (GM), AT and T (T), United Technologies (UTX)
Whether you are a trader or an investor, you were probably as happy as Tom Cruise's "Joel" character in
Risky Business to hear the closing bell today. Things were looking so promising this week that the media was pondering whether the bottom of the market had come and gone. That part remains unknown that feeling of bear market rallies has returned. The good news is that the auto snag did not bring about the massive down day as a recovery came in. The retail sales data came in slightly
"less-bad" than expected.
General Motors Corporation (NYSE:
GM) and
Ford Motor Company (NYSE:
F) were the two bogeys today. Their fate lies in the chances of NOT going bankrupt, and the cancellation of the bailout from the Senate was only greeted by less selling than one would expected when you saw 20% drops and worse in early trading. The good news is that this did not destroy most stocks as much as many feared earlier today, with GM even managing some gains by the end of the day.
Here are today's unofficial closing bell levels:
Dow 8,629.68 +64.59 (0.75%)
S&P 500 879.74 +6.15 (0.70%)
Nasdaq 1,540.72 +32.84 (2.18%)
Top Analyst DowngradesTop Analyst Upgrades
Continue reading Closing Bell: Market up, GM up slightly
Posted Jun 27th 2008 3:33PM by Brent Archer (RSS feed)
Filed under: Major movement, Analyst reports, Good news, Bristol-Myers Squibb (BMY), Options, Technical Analysis
Bristol-Myers Squibb (NYSE:
BMY) shares are trading higher today after
a Bernstein analyst wrote that BMY might be a takeover candidate, one day after the company announced it has
completed its $234.6 million acquisition of Kosan Biosciences. If you think that the stock won't fall by too much in the coming months, then now could be a good time to look at a bullish hedged trade on BMY.
After hitting a one-year high of $32.35 in July, the stock hit a one-year low of $19.43 last week. BMY opened this morning at $20.06. So far today the stock has hit a low of $20.00 and a high of $20.60. As of 12:50, BMY is trading at $20.45, up 78 cents (4.0%). The chart for BMY looks bearish and steady, while
S&P gives the stock a positive 4 STARS (out of 5) buy rating.
For a bullish hedged play on this stock, I would consider a September
bull-put credit spread below the $17.50 range. A bull-put credit spread is an options position that combines the purchase and sale of put options to hedge risk in case the stock doesn't do what you think but still leverage nice returns. For this particular trade, we will make an 11.1% return in just three months as long as BMY is above $17.50 at September expiration. BMY would have to fall by more than 14% before we would start to lose money. Learn more about this type of trade
here.
BMY hasn't been below $19.40 at all in the past year and has shown support around $19.50 recently. This trade could be risky if the company's earnings (due out on 7/24) disappoint, but even if that happens, this position could be protected by the support the stock might find from bargain hunters looking for defensive stocks.
Brent Archer is an options analyst and writer at Investors Observer.
DISCLOSURE: Mr. Archer owns and/or controls diversified portfolios of long and short stock and option positions that may include holdings in companies he writes about. At publication time, Brent neither owns nor controls positions in BMY.Posted Jan 19th 2007 9:30AM by Hilary Kramer (RSS feed)
Filed under: Bristol-Myers Squibb (BMY), Hilary On Stocks

Since December 2000, Bristol Myers Squibb Co's (NYSE: BMY) stock price has disappointed even the most loyal of shareholders. However, this Big Pharma stalwart is finally poised for some serious growth and to provide some joy to those who have weathered the ski slope downward followed by years of flat line stock movement.
Revenues haven't grown since 2004, and many of the company's patents have expired, leaving them open to generic drug competitors. There have been some questions about accounting as well as some improprieties that have cost BMY significant money to settle government investigations.
But the company has been plowing money into R&D, and now has several drugs in the pipeline that promise to send this stock up in the coming year. These new products treat a range of ailments from hypertension to HIV to cancer to arthritis, and I think they'll be enough to send the stock price over $30 for the first time in more than four years.
To be sure, BMY still has a few things to worry about. The Democrats have already passed a bill in the House that would allow the government to negotiate pharmaceutical prices for Medicare. The bill has yet to pass the Senate and the president has threatened a veto, but if it passes, it will hurt revenues for BMY and other drug companies. The Democrats also have bipartisan support for a bill that would prevent big companies like BMY from paying generic manufacturers to keep their products off the market for a few years. This too could put a damper on revenues.
BMY also faces a more specific threat from Apotex, a Canadian generic manufacturer that has an anti-clotting drug that would compete with Plavix, a major seller for BMY. There is an injunction against this generic drug right now and the companies have gone to court to determine whether the generic drug can be sold. If BMY loses, it will take a serious hit.
One or more of these potential problems may never come to pass. Regardless, I think BMY is turning a corner and its new portfolio of products will be enough to make this a good bet for 2007.
Type of stock: One of the largest pharmaceutical companies that is on the verge of releasing a number of important revenue-driving drugs.
Price target: BMY has been gaining ground recently and is near the top of its 52-week range. I'd grab it now and ride it above $30 by year-end. There is a nice little dividend to boost your profits even more.
Hilary Kramer is a financial editor and money coach for AOL and an authority on investing. Visit her at www.hilarykramer.com.
Posted Sep 11th 2006 9:08PM by Sarah Gilbert (RSS feed)
Filed under: Bad news, Rumors, Management
Bristol-Myers Squibb (NYSE:BMY)'s CEO, Peter R. Dolan and General Counsel, Richard K. Willard, will be fired if the company's board of directors agrees with recommendations from an independent monitor. The Wall Street Journal made the unusual move of posting a "breaking news" notice on its web site in advance of the full story.
While Dolan's self-importance is such that the company's "about us" web page features his name, under "CEO:" as the first (and only managerial) Very Important Detail, he's made such gigantic missteps that a recent article said he had "precious little credibility." His attempts to delay generic competition for Plavix are being investigated by the Justice Department, and he's been responsible for "major financial scandals."
Today's Forbes asks, "Who Could Replace Peter Dolan?" and offers up names such as CFO Andrew Bonfield, Chief Scientific Officer Elliot Sigal (a "dark horse") and Karen Katen, Vice Chairman of Pfizer. We'll provide more details as we see them.